The Pulmonary Vascular and Interstitial lung diseases therapeutic area is dedicated to researching, developing, and delivering innovative solutions that can change the course of low-prevalence and often serious diseases that affect the small blood vessels of the lungs and the interstitial space between them and the pulmonary alveoli.
These diseases are characterized by a wide range of symptoms, including shortness of breath (dyspnea), with or without physical activity, cough and chronic fatigue, which can progressively lead to respiratory failure and, finally, death or transplantation. They are, therefore, diseases that significantly limit the quality of life of patients and cause a great emotional and social impact, not only on them but also on their caregivers.
The diagnosis and treatment of these diseases continues to be a challenge for health professionals, so it is urgent to deepen their research in order to alleviate this deficit.
Data may vary between studies and populations. The information included here comes from peer-reviewed scientific literature.
